SCHEMBL4124488

SCHEMBL4124488

COc1cccc(C(O)c2cc(Cl)c(C)cc2NC(=O)O)c1OC

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
LMNA P02545 3/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
NPSR1 Q6W5P4 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MAPT P10636 6/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 2/20 0.48
HTT P42858 1/20 0.48
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111602 0.89 LMNA (0.44) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL13775916 0.87 LMNA (0.51) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4123578 0.86 LMNA (0.43) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4109266 0.80 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4124464 0.78 LPAR1 (0.43) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4122598 0.77 TAS1R3 (0.42) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4116747 0.77 LPAR1 (0.45) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4124875 0.76 LPAR1 (0.45) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4127954 0.76 NPC1 (0.41) ALDH1A1NPC1RAB9ANPSR1KDM4E
SCHEMBL13775927 0.76 KDM4E (0.39) ALDH1A1SMN1; SMN2LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR ALDH1A1 1587/4885SMN1; SMN2 4445/4885LMNA 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.